Advertisement

Beta-Lactam Antibiotics

  • Melinda M. Neuhauser
  • Larry H. Danziger
Chapter
Part of the Infectious Disease book series (ID)

Abstract

The beta-lactam antibiotics are a large class of diverse compounds used clinically in both the oral and parenteral forms. The beta-lactam antibiotic agents have become the most widely used therapeutic class of antimicrobials because of their broad antibacterial spectrum and excellent safety profile. Reports of drug—drug interactions with the beta-lactam antimicrobials are a relatively rare phenomenon, and when they do occur they are generally of minor significance. This chapter describes the drug—drug interactions of the beta-lactam antibiotics: penicillins, cephalosporins, carbepenems, and monobactams.

Keywords

Valproic Acid Antimicrob Agent Penicillin Versus Cyclosporine Concentration Cefpodoxime Proxetil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rogers HJ, James CA, Morrison PJ. Effect of cimetidine on oral absorption of ampicillin and cotrimoxazole. J Antimicrob Chemother 1980; 6: 297–300.PubMedGoogle Scholar
  2. 2.
    Paulsen O, Hoglund P, Walder M. No effect of omeprazole-induced hypoacidity on the bioavailability of ampicillin and bacampicillin. Scand J Infec Dis 1989; 21: 219–223.Google Scholar
  3. 3.
    Stainforth DH, Clarke HL, Horton R, et al. Augmentin bioavailability following cimetidine, aluminum hydroxide and milk. Int J Clin Pharmacol Ther Toxicol 1985; 23: 154–157.Google Scholar
  4. 4.
    Deppermann KM, Lode H, Hoffken G, et al. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989; 33: 1901–1907.PubMedGoogle Scholar
  5. 5.
    Sommers DK, Van Wyk M, Moncrieff J. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharm 1984: 18: 535–539.Google Scholar
  6. 6.
    Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol 1981; 21: 456–458.PubMedGoogle Scholar
  7. 7.
    Fessel WJ. Immunologic reactivity in hyperuricemia. N Engl J Med 1972; 286: 1218.PubMedGoogle Scholar
  8. 8.
    Townsend RS. In vitro inactivation of gentamicin by ampicillin. Am J Hosp Pharm 1989; 46: 2250–2251.PubMedGoogle Scholar
  9. 9.
    McLaughlin JE, Reeves DS. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. Lancet 1971; 1: 261–264.PubMedGoogle Scholar
  10. 10.
    Uber WE, Brundage RC, White RL, et al. In vivo inactivation of tobramycin by piperacillin. DICP Ann Pharmacother 1991; 25: 357–359.Google Scholar
  11. 11.
    Halstenson CE, Hirata CA, Heim-Duthoy KL, et al. Effect of concomitant administration of piperacillin on the disposition of netilmicin and tobramycin in patients with end-stage renal disease. Antimicrob Agents Chemother 1990; 34: 128–133.PubMedGoogle Scholar
  12. 12.
    Davies M, Morgan JR, Anand C. Interactions of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother 1975; 7: 431–434.PubMedGoogle Scholar
  13. 13.
    Weibert R, Keane W, Shapiro F. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure. Trans Am Soc Artif Organs 1976; 22: 439.Google Scholar
  14. 14.
    Eykyn S, Philips I, Ridley M. Gentamicin plus carbenicillin. Lancet 1 1971; 13: 545, 546.Google Scholar
  15. 15.
    Davies M, Morgan JR, Anand C. Interactions of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother 1975: 7: 431–434.PubMedGoogle Scholar
  16. 16.
    Kradjian WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med 1980; 140: 1668–1670.Google Scholar
  17. 17.
    Lau A, Lee M, Flascha S, et al. Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 1983; 24: 533–537.PubMedGoogle Scholar
  18. 18.
    Hitt CM, Patel KB, Nicolau DP, Zhu Z, Nightingale CH. Influence of piperacillintazobactam on pharmacokinetics of gentamicin given once daily. Am J Health Syst Pharm 1997; 1: 2704–2708.Google Scholar
  19. 19.
    Noone P, Pattison JR. Therapeutic implications of interaction of gentamicin and penicillins. Lancet 1971; 2: 575–578.PubMedGoogle Scholar
  20. 20.
    Ervin FR, Bullock WE, Nuttall CE. Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother 1976; 9: 1009–1011.Google Scholar
  21. 21.
    Cheng SH, White A. Effect of orally administered neomycin on the absorption of penicillin V. N Engl J Med 1962; 267: 1296–1297.PubMedGoogle Scholar
  22. 22.
    Moellering RC, Wennersten C, Weinberg AN. Synergy of penicillin and gentamicin against Enterococci. J Infect Dis 1971; S124: 207.Google Scholar
  23. 23.
    Guenthner SH, Chao HP, Wenzel RP. Synergy between amikacin and ticarcillin or mezlocillin against nosocomial bloodstream isolates. J Antimicrob Chemother 1986; 18: 550–552.PubMedGoogle Scholar
  24. 24.
    Laverdiere M, Gallimore B, Restieri C, et al. In vitro synergism of ceftriaxone combined with aminoglycosides against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1994; 19: 39–46.PubMedGoogle Scholar
  25. 25.
    Marks MI, Hammerberg S, Greenstone G, et al. Activity of newer aminoglycosides and carbenicillin, alone, and in combination against gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1976; 10: 399–401.PubMedGoogle Scholar
  26. 26.
    Moellering RC, Wennersten, Weinberg AJ. Studies on antibiotic synergism against Enterococci. I. Bacteriologic studies. J Lab Clin Med 1971; 77: 821–828.PubMedGoogle Scholar
  27. 27.
    Weinstein AJ, Moellering RC. Penicillin and gentamicin therapy for enterococcal infections. JAMA 1973; 223: 1030–1032.PubMedGoogle Scholar
  28. 28.
    Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of Gram-negative rod bacteremia. Chemotherapy 1978; 24: 45–54.PubMedGoogle Scholar
  29. 29.
    Brown CH, Natelson EA, Bradshaw MW, et al. The hemostatic defect produced by carbenicillin. N Engl J Med 1974; 291: 265–270.PubMedGoogle Scholar
  30. 30.
    Brown CH, Natelson EA, Bradshaw MW, et al. Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother 1975; 7: 652–657.PubMedGoogle Scholar
  31. 31.
    Brown CH, Bradshaw MW, Natelson EA, et al. Defective platelet function following the administration of penicillin compounds. Blood 1976; 6: 949–956.Google Scholar
  32. 32.
    Andrassy K, Ritz E, Hasper B, et al. Penicillin-induced coagulation disorder. Lancet 1976; 2: 1039–1041.PubMedGoogle Scholar
  33. 33.
    Andrassy K, Weischedel E, Ritz E, et al. Bleeding in uremic patients after carbenicillin. Thrombos Haemost 1976; 36: 115–126.Google Scholar
  34. 34.
    Tabernero Romo JM, Corbacho L, Sanchez S, et al. Effects of carbenicillin on blood coagulation; a study in patients with chronic renal failure. Clin Nephrol 1979; 11: 31–34.Google Scholar
  35. 35.
    Wisloff F, Larsen JP, Dahle A, et al. Effect of prophylactic high-dose treatment with ampicillin and cloxacillin on bleeding time and bleeding in patients undergoing elective vascular surgery. Scand J Haematol 1983; 31: 97–101.PubMedGoogle Scholar
  36. 36.
    Lurie A, Ogilvie M, Gold CH, et al. Carbenicillin-induced coagulopathy. S Afr Med J 1974; 48: 457–461.PubMedGoogle Scholar
  37. 37.
    Taylor AT, Pritchard DC, Goldstein AO, et al. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994; 39: 182–185.PubMedGoogle Scholar
  38. 38.
    Heilker GM, Fowler JW, Self TH, et al. Possible nafcillin-warfarin interaction. Arch Intern Med 1994; 154: 822–824.PubMedGoogle Scholar
  39. 39.
    Qureshi GD, Reinders TP, Somori GJ, et al. Warfarin resistance with nafcillin therapy. Ann Intern Med 1984; 100: 527–529.PubMedGoogle Scholar
  40. 40.
    Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. Drug Intell Clin Pharm 1991; 25: 598–600.Google Scholar
  41. 41.
    Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm 1987; 6: 804–806.PubMedGoogle Scholar
  42. 42.
    Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. Ann Pharmacother 1996: 30: 1402–1407.PubMedGoogle Scholar
  43. 43.
    Davis RL, Berman W, Wernly JA, et al. Warfarin-nafcillin interaction. J Pediatr 1991; 118: 300–303.PubMedGoogle Scholar
  44. 44.
    Rolinson GN, Sutherland R. The binding of antibiotics to serum proteins. Br J Pharmacol 1965; 25: 638–650.Google Scholar
  45. 45.
    Brown MA, Korchinski ED, Miller DR. Interaction of penicillin-G and warfarin? Can J Hosp Pharm 1979; 32: 18, 19.Google Scholar
  46. 46.
    Kampmann J, Molholm Hansen J, Siersbaek-Nielsen K, Laursen H. Effect of some drugs on penicillin half-life in blood. Clin Pharmacol Ther 1972; 13: 516–519.PubMedGoogle Scholar
  47. 47.
    Kunin CM. Clinical pharmacology of the new penicillins. II. Effect of drugs which interfere with binding to serum proteins. Clin Pharmacol Ther 1966; 7: 180–188.PubMedGoogle Scholar
  48. 48.
    Suffness M, Rose BS. Potential drug interactions and adverse effects related to aspirin. Drug Intell Clin Pharm 1974; 8: 694–699.Google Scholar
  49. 49.
    Moskowitz B, Somani SM, McDonald RH. Salicylate interaction with penicillin and seco-barbital binding sites on human serum albumin. Clin Toxicol 1973; 6: 247–256.PubMedGoogle Scholar
  50. 50.
    Hayes AH. Therapeutic implications of drug interactions with acetaminophen and aspirin. Arch Intern Med 1981: 141: 301–304.PubMedGoogle Scholar
  51. 51.
    Schafer-Korting M, Kirch W, Axthelm T, et al. Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther 1983; 33: 283–288.PubMedGoogle Scholar
  52. 52.
    McLean AJ, Tonkin A, McCarthy P, et al. Dose-dependence of atenolol-ampicillin interaction. Br J Clin Pharmacol 1984; 18: 969–971.PubMedGoogle Scholar
  53. 53.
    Westphal JF, Trouvin JH, Deslandes A, et al. Nifedipine enhances amoxicillin absorption kinetics and bioavailability in humans. J Pharmacol Exp Ther 1990; 255: 312–317.PubMedGoogle Scholar
  54. 54.
    Jawetz E. Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on Enterococci in vitro. Science 1950; 3: 254–256.Google Scholar
  55. 55.
    Wallace JF, Smith H, Garcia M, et al. Studies on the pathogenesis of meningitis. VI Antagonism between penicillin and chloramphenicol in experimental pneumococcal meningitis. J Lab Clin Med 1967; 70: 408–418.PubMedGoogle Scholar
  56. 56.
    Yourassowsky E, Monsieur R. Antagonism limit of penicillin G and chloramphenicol against Neisseria meningitidis. Arzneimittel Forsch 1971; 21: 1385–1387.Google Scholar
  57. 57.
    Gjessing HC, Odegaard K. Oral chloramphenicol alone and with intramuscular procaine penicillin in the treatment of gonorrhoea. Br J Vener Dis 1967; 43: 133–136.PubMedGoogle Scholar
  58. 58.
    DeRitis F, Giammanco G, Manzillo G. Chloramphenicol combined with ampicillin in treatment of typhoid. Br Med J 1972; 4: 17, 18.Google Scholar
  59. 59.
    Ali HM. Reduced ampicillin bioavailability following oral coadministration with chloroquine. J Antimicrob Chemother 1985; 15: 781–784.PubMedGoogle Scholar
  60. 60.
    Barriere SL, Catlin DH, Orlando PL, et al. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother 1990; 34: 823–826.PubMedGoogle Scholar
  61. 61.
    Peterson LR, Moody JA, Fasching CE, et al. In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model. Diagn Microbiol Infect Dis 1987; 7: 127–136.PubMedGoogle Scholar
  62. 62.
    Dossetor J. Drug interaction with oral contraceptive steroids [editorial]. Br Med J 1980; 280: 467, 468.Google Scholar
  63. 63.
    DeSano EA, Hurley SC. Possible interaction of antihistamines and antibiotics with oral contraceptive effectiveness. Fertil Steril 1982; 1: 853, 854.Google Scholar
  64. 64.
    Bainton R. Interaction between antibiotic therapy and contraceptive medication. Oral Surg Oral Med Oral Pathol 1986; 61: 453–455.PubMedGoogle Scholar
  65. 65.
    Silber TJ. Apparent oral contraceptive failure associated with antibiotic administration. J Adolesc Health Care 1983; 4: 287–289.PubMedGoogle Scholar
  66. 66.
    Miller DM, Helms SE, Brodell RT. A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 1994; 30: 1008–1011.PubMedGoogle Scholar
  67. 67.
    Fernandez N, Sierra M, Diez MJ, et al. Study of the pharmacokinetic interaction between ethinylestradiol and amoxicillin in rabbits. Contraception 1997: 55: 47–52.PubMedGoogle Scholar
  68. 68.
    Back DJ, Brenckenridge AM, Cross KJ, et al. An antibiotic interaction with ethinyloestradiol in the rat and rabbit. J Steroid Biochem 1982; 16: 407–413.PubMedGoogle Scholar
  69. 69.
    Back DJ, Breckenridge AM, Maclver M, et al. The effects of ampicillin on oral contraceptive steroids in women. Br J Clin Pharmacol 1982; 14: 43–48.PubMedGoogle Scholar
  70. 70.
    Friedman CI, Huneke AL, Kim MH, et al. The effect of ampicillin on oral contraceptive effectiveness. Obstet Gynecol 1980; 55: 33–37.PubMedGoogle Scholar
  71. 71.
    Joshi JV, Joshi UM, Sankholi GM, et al. A study of interaction of low-dose combination oral contraceptive with ampicillin and metronidazole. Contraception 1980; 22: 643–652.PubMedGoogle Scholar
  72. 72.
    Veremis SA, Maddux MS, Pollak R, et al. Subtherapeutic cyclosporine concentrations during nafcillin therapy. Transplantation 1987; 43: 913–915.PubMedGoogle Scholar
  73. 73.
    Finland M, Bach MC, Garner C, et al. Synergistic action of ampicillin and erythromycin against Nocardia asteroides: effect of time of incubation. Antimicrob Agents Chemother 1974; 5: 344–353.PubMedGoogle Scholar
  74. 74.
    Roberts CE, Rosenfeld LS, Kirby WM. Synergism of erythromycin and penicillin against resistant staphylococci: mechanism and relation to synthetic penicillins. Antimicrob Agents Chemother 1962: 831–842.Google Scholar
  75. 75.
    Waterworth PM. Apparent synergy between penicillin and erythromycin or fusidic acid. Clin Med 1963: 70: 941–953.PubMedGoogle Scholar
  76. 76.
    Oswald EJ, Reedy RJ, Wright WW. Antibiotic combinations: an in vitro study of antistaphylococcal effects of erythromycin plus penicillin, streptomycin, or tetracycline. Antimicrob Agents Chemother 1961: 904–910.Google Scholar
  77. 77.
    Herrell WE, Balows A, Becker J. Erythrocillin: a new approach to the problem of antibiotic-resistant Staphylococci. Antibiot Med Clin Ther 1960; 7: 637–642.Google Scholar
  78. 78.
    Manten A. Synergism and antagonism between antibiotic mixtures containing erythromycin. Antibiot Chemother 1954; 4: 1228–1233.Google Scholar
  79. 79.
    Allen NE, Epp JK. Mechanism of penicillin-erythromycin synergy on antibiotic resistant Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13: 849–853.PubMedGoogle Scholar
  80. 80.
    Manten A, Terra JI. The antagonism between penicillin and other antibiotics in relation to drug concentration. Chemotherapia 1964; 8: 21–29.Google Scholar
  81. 81.
    Chang TW, Weinstein L. Inhibitory effects of other antibiotics on bacterial morphologic changes induced by penicillin G. Nature 1966: 211: 763–765.PubMedGoogle Scholar
  82. 82.
    Strom J. Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them. Antibiot Chemother 1961; 11: 694–697.PubMedGoogle Scholar
  83. 83.
    Bach MC, Monaco AP, Finland M. Pulmonary nocardiosis therapy with minocycline and with erythromycin plus ampicillin. JAMA 1973; 224: 1378–1381.PubMedGoogle Scholar
  84. 84.
    Robinson L, Fonseca K. Value of the minimum bactericidal concentration of antibiotics in the management of a case of recurrent Streptococcus bovis septicaemia. J Clin Pathol 1982; 35: 879, 880.Google Scholar
  85. 85.
    Garrod LP, Waterworth PM. Methods of testing combined antibiotic bactericidal action and the significance of the results. J Clin Pathol 1962; 15: 328–338.PubMedGoogle Scholar
  86. 86.
    Huupponen R, Seppala P, lisalo E. Effect of guar gum, a fibre preparation on digoxin and penicillin absorption in man. Eur J Clin Pharmacol 1984; 26: 279–281.PubMedGoogle Scholar
  87. 87.
    Attef OA, Ali AA. Effect of khat chewing on the bioavailability of ampicillin and amoxycillin. J Antimicrob Chemother 1997; 39: 523–525.PubMedGoogle Scholar
  88. 88.
    Iven H, Brasch H. The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother Pharmacol 1988; 21: 337–342.PubMedGoogle Scholar
  89. 89.
    Iven H, Brasch H. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemother Pharmacol 1986; 17: 218–222.PubMedGoogle Scholar
  90. 90.
    Najjar TA, Abou-Auda HS, Ghilzai NM. Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. Cancer Chemother Pharmacol 1998: 42: 423–428.PubMedGoogle Scholar
  91. 91.
    Iven H, Brasch H. Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother Pharmacol 1990; 26: 139–143.PubMedGoogle Scholar
  92. 92.
    Yamamoto K, Sawada Y, Mutsashita Y, et al. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother 1997; 31: 1261–1262.PubMedGoogle Scholar
  93. 93.
    Bloom NJ, Ignoffo RJ, Reis CA, et al. Delayed clearance (Cl) of methotrexate (MTX) associated with antibiotics and antiinflammatory agents [abstr]. Clin Res 1986; 34: 560A.Google Scholar
  94. 94.
    Nierenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction [letter]. Arch Dermatol 1983; 119: 449, 450.Google Scholar
  95. 95.
    Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol 1992; 14: 88–92.PubMedGoogle Scholar
  96. 96.
    Gilman AG, et al. (ed.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, New York: McGraw-Hill, 1996.Google Scholar
  97. 97.
    Dasgupta A, Sperelakis A, Mason A, et al. Phenytoin-oxacillin interactions in normal and uremic sera. Pharmacotherapy 1997; 17: 375–378.PubMedGoogle Scholar
  98. 98.
    Dasgupta A, Dennen DA, Dean R, et al. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole. Clin Chem 1991; 37: 98–100.PubMedGoogle Scholar
  99. 99.
    Welling PG, Selen SD, Kendall MJ, et al. Probenecid: an unexplained effect on cephalosporin pharmacology. Br J Clin Pharma 1979; 8: 491–495.Google Scholar
  100. 100.
    Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther 1968; 9: 345–349.PubMedGoogle Scholar
  101. 101.
    Barbhaiya R, Thin RN, Turner P, et al. Clinical pharmacological studies of amoxycillin: effect of probenecid. Br J Vener Dis 1979; 55: 211–213.PubMedGoogle Scholar
  102. 102.
    Ziv G, Sulman FG. Effects of probenecid on the distribution, elimination, and passage into milk of benzylpenicillin, ampicillin, and cloxacillin. Arch Int Pharmacodyn Ther 1974; 207: 373–382.PubMedGoogle Scholar
  103. 103.
    Shanson DC, McNabb R, Hajipieris P. The effect of probenecid on serum amoxycillin concentrations up to 18 hours after a single 3 g oral dose of amoxycillin: possible implications for preventing endocarditis. J Antimicrob Chemother 1984; 13: 629–632.PubMedGoogle Scholar
  104. 104.
    Waller ES, Sharanevych MA, Yakatan GJ. The effect of probenecid on nafcillin disposition. J Clin Pharmacol 1982; 22: 482–489.PubMedGoogle Scholar
  105. 105.
    Corvaia L, Li SC, Ioannides-Demos LL, et al. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. J Antimicrob Chemother 1992; 30: 875–878.PubMedGoogle Scholar
  106. 106.
    Krogsgaard MR, Hansen BA, Slotsbjerg T, et al. Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid. Pharmacol Toxicol 1994; 74: 181–184.PubMedGoogle Scholar
  107. 107.
    Ganes D, Batra A, Faulkner D, et al. Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers. Pharm Res 1991; 8: S299.Google Scholar
  108. 108.
    Speck RS, Jawetz E, Gunnison JB. Studies on antibiotic synergism and antagonism. The interference of aureomycin or terramycin with the action of penicillin in infections in mice. Arch Intern Med 1951; 88: 168–174.Google Scholar
  109. 109.
    Gunnison JB, Coleman VR, Jawetz E. Interference of aureomycin and of terramycin with the action of penicillin in vitro. Proc Soc Exp Biol Med 1950; 75: 549–452.PubMedGoogle Scholar
  110. 110.
    Lepper MH, Dowling HP. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillin and aureomycin. Arch Intern Med 1951: 88: 489–494.Google Scholar
  111. 111.
    Olsson RA, Kirby JC, Romansky MJ. Pneumococcal meningitis in the adult. Clinical, therapeutic and prognostic aspects in forty-three patients. Ann Intern Med 1961; 55: 545–549.PubMedGoogle Scholar
  112. 112.
    Strom J. The question of antagonism between penicillin and chlortetracycline, illustrated by therapeutical experiments in scarlatina. Antibiot Med 1955; 1: 6–12.PubMedGoogle Scholar
  113. 113.
    Ahern JJ, Kirby WMM. Lack of interference of aureomycin in treatment of pneumococcic pneumonia. Arch Intern Med 1953; 91: 197–203Google Scholar
  114. 114.
    Tryba M. Potentiation of non-depolarizing muscle relaxants of acetylaminopenicillin. Studies on the example of vecuronium [English abstr]. Anaethesist 1985; 34: 651–655.Google Scholar
  115. 115.
    Singh YN, Harvey AL, Marshall IG. Antibiotic-induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility by calcium and by neostigmine. Anesthesiology 1978; 48: 418–424.PubMedGoogle Scholar
  116. 116.
    Harwood TN, Moorthy SS. Prolonged vecuronium-induced neuromuscular blockade in children. Anesth Analg 1989; 68: 534–536.PubMedGoogle Scholar
  117. 117.
    Mackie K, Pavlin EG. Recurrent paralysis following pipercillin administration. Anesthesiology 1990; 72: 561–563.PubMedGoogle Scholar
  118. 118.
    Condon RE, Munshi CA, Arfman RC. Interaction of vecuronium with pipercillin or cefoxitin evaluated in a prospective, randomized, double-blind clinical trial. Am Surg 1995; 61: 403–406.PubMedGoogle Scholar
  119. 119.
    Kadlec GJ, Ha LH, Jarboe CH, et al. Effect on ampicillin on theophylline half-life in infants and young children. South Med J 1978; 71: 1584.PubMedGoogle Scholar
  120. 120.
    Jonkman JH, Van der Boon WJ, Schoenmaker R, et al. Lack of effect of amoxicillin on theophylline pharmacokinetics. Br J Clin Pharmacol 1985; 19: 99–101.PubMedGoogle Scholar
  121. 121.
    Matera MG, Cazzola M, Lampa E, et al. Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis. J Chemother 1993; 5: 233–236.PubMedGoogle Scholar
  122. 122.
    Cazzola M, Santangelo G, Guidetti E, et al. Influence of sulbactam plus ampicillin on theophylline clearance. Int J Clin Pharmacol Res 1991; 11: 11–15.PubMedGoogle Scholar
  123. 123.
    Jonkman JH, Van der Boon WJ, Schoenmaker R, et al. Clinical pharmacokinetics of amoxycillin and theophylline during cotreatment with both medicaments. Chemotherapy 1985; 31: 329–335.PubMedGoogle Scholar
  124. 124.
    Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989; 46: 674–685.PubMedGoogle Scholar
  125. 125.
    Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36: 796–800.PubMedGoogle Scholar
  126. 126.
    Plager JE. Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease. Cancer 1976; 37: 1937–1943.PubMedGoogle Scholar
  127. 127.
    Wade JC, Smith CR, Petty BG, et al. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978; 2: 604–606.PubMedGoogle Scholar
  128. 128.
    Gurwich EL, Sula J, Hoy RH. Gentamicin-cephalothin drug reaction. Am J Hosp Pharm 1978; 35: 1402, 1403.Google Scholar
  129. 129.
    Hansen MM, Kaaber K. Nephrotoxicity in combined cephalothin-gentamicin therapy among patients severely ill with malignant disease. Cancer 1976; 37: 1937–1943.Google Scholar
  130. 130.
    Cabanillas F, Burgos RC, Rodriquez RC, et al. Nephrotoxicity of combined cephalothingentamicin regimen. Arch Intern Med 1975; 135: 850–852.PubMedGoogle Scholar
  131. 131.
    Fillastre JP, Laumonier R, Humbert G, et al. Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J 1973; 2: 396, 397.Google Scholar
  132. 132.
    Bobrow SL, Jaffe E, Young RC, et al. Anuria and acute tubular necrosis associated with gentamicin and cephalothin. JAMA 1972; 222: 1546, 1547.Google Scholar
  133. 133.
    Foord RD. Cephaloridine, cephalothin, and the kidney. J Antimicrob Chemother 1975; 1 (suppl): 119–133.PubMedGoogle Scholar
  134. 134.
    Barza M, Pinn V, Tanguay P, et al. Nephrotoxicity of newer cephalosporins and aminoglycosides alone and in combination in a rat model. J Antimicrob Chemother 1978; 4: 59–68.PubMedGoogle Scholar
  135. 135.
    Bloch R, Luft FC, Rankin LI. Protection from gentamicin nephrotoxicity by cephalothin and carbenicillin. Antimicrob Agents Chemother 1979; 15: 46–49.PubMedGoogle Scholar
  136. 136.
    Dellinger P, Murphy T, Pinn V, et al. Protective effect of cephalothin against gentamicininduced nephrotoxicity in rats. Antimicrob Agents Chemother 1976; 9: 172–178.PubMedGoogle Scholar
  137. 137.
    Harrison WO, Silverblatt FJ, Turck M. Gentamicin nephrotoxicity: failure of three cephalosporins to potentiate injury to rats. Antimicrob Agents Chemother 1975; 8: 209–215.PubMedGoogle Scholar
  138. 138.
    Bendirdjian JP, Prime DJ, Browning MC, et al. Additive nephrotoxicity of cephalosporins and aminoglycosides in the rabbit. J Pharmacol Exp Ther 1981; 218: 681–685.PubMedGoogle Scholar
  139. 139.
    OmnicefjM Packet insert. Parke-Davis, 1998.Google Scholar
  140. 140.
    Satterwhite JH, Cerimele BJ, Coleman DL. Pharmacokinetics of cefaclor AF: effects of age, antacids, and H2-receptor antagonists. Postgrad Med J 1992; 68: S3 - S9.PubMedGoogle Scholar
  141. 141.
    Healy DP, Sahia J, Sterling LP, et al. Influence of antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. Antimicrob Agents Chemother 1989; 33: 1994–1997.PubMedGoogle Scholar
  142. 142.
    Deslandes A, Camus F, Lacroix C, et al. Effects of nifedipine and diltiazem on pharmacokinetics of cefopdoxime following its oral administration. Antimicrob Agents Chemother 1996; 40: 2879–2881.PubMedGoogle Scholar
  143. 143.
    Duverne C, Bouten A, Deslandes A, et al. Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimicrob Agents Chemother 1992; 36: 2462–2467.PubMedGoogle Scholar
  144. 144.
    Marino EL, Vicente MT, Dominguez-Gil A. Influence of cholestyramine on the pharmacokinetic parameters of cefadroxil after simultaneous administration. Int J Pharmaceut 1983; 16: 23–30.Google Scholar
  145. 145.
    Parsons RL, Paddock GM, Hossack GM. Cholestryamine induced antibiotic malabsorption. Chemotherapy 4. In: Williams JD, Geddes AM (eds.). Pharmacology of Antibiotics. New York-London: Plenum, 1975; pp. 191–198.Google Scholar
  146. 146.
    Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857–868.PubMedGoogle Scholar
  147. 147.
    Adler S, Segel DP. Nonoliguric renal failure secondary to sodium colistimethate: a report of four cases. Am J Med Sci 1971; 262: 109–114.PubMedGoogle Scholar
  148. 148.
    Kannangara DW, Gallagher K, Lefrock JL. Disulfiram-like reactions with newer cephalosporins: cefmenoxime. Am J Med Sci 1984; 287: 45–47.Google Scholar
  149. 149.
    Foster TS, Raehl CL, Wilson HD. Disulfiram-like reaction associated with a parenteral cephalosporin. Am J Hosp Pharm 1980; 37: 858, 859.Google Scholar
  150. 150.
    Uri JV, Parks DB. Disulfiram-like reaction to certain cephalosporins. Ther Drug Monit 1983; 5: 219–224.PubMedGoogle Scholar
  151. 151.
    Kleinknecht D, Jungers P, Fillastre JP. Nephrotoxicity of cephaloridine. Ann Intern Med 1974; 80: 421, 422.Google Scholar
  152. 152.
    Dodds MG, Foord RD. Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine. Br J Pharmacol 1970; 40: 227–236.PubMedGoogle Scholar
  153. 153.
    Norrby R, Stenqvist K, Elgefors B, et al. Interaction between cephaloridine and furosemide in man. Scand J Infect Dis 1976; 8: 209–212.PubMedGoogle Scholar
  154. 154.
    Simpson U. Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine. N Z Med J 1971; 74: 312–315.PubMedGoogle Scholar
  155. 155.
    Trollfors B, Norrby R, Kristianson K. Effects on renal function of treatment with cefoxitin sodium alone or in combination with furosemide. J Antimicrob Chemother 1978; 4: S85 - S89.Google Scholar
  156. 156.
    Korn A, Eichler HG, Gasic S. A drug interaction study of ceftriaxone and frusemide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1986; 24: 262–264.PubMedGoogle Scholar
  157. 157.
    Walstad RA, Dahl K, Hellum KB, et al. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy. Eur J Clin Pharmacol 1988; 35: 273–279.PubMedGoogle Scholar
  158. 158.
    Ueno K, Tanaka K, Tsujimura K, et al. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther 1993; 54: 473–475.PubMedGoogle Scholar
  159. 159.
    Shukla UA, Pittman KA, Barbhiaya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol 1992; 32: 725–731.PubMedGoogle Scholar
  160. 160.
    Neu HC. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. Annu Rev Pharmacol Toxicol 1982; 22: 599–642.PubMedGoogle Scholar
  161. 161.
    Merle-Melet M, Bresler L, Lokiec F, et al. Effects of diclofenac on ceftriaxone pharmacokinetics in humans. Antimicrob Agents Chemother 1992; 36: 2331–2333.PubMedGoogle Scholar
  162. 162.
    Andrassy K, Bechtold H, Ritz E. Hypoprothrombinemia caused by cephalosporins. J Antimicrob Chemother 1985; 15: 133–136.PubMedGoogle Scholar
  163. 163.
    Freedy HR, Cetnarowski AB, Lumish RM, et al. Cefoperazone-induced coagulopathy. Drug Intell Clin Pharm 1986; 20: 281–283.PubMedGoogle Scholar
  164. 164.
    Rymer W, Greenlaw CW. Hypoprothrombinemia associated with cefamandole. Drug Intell Clin Pharm 1980; 40; 780–783.Google Scholar
  165. 165.
    Osborne JC. Hypoprothrombinemia and bleeding due to cefoperazone [letter]. Ann Intern Med 1985; 102: 721, 722.Google Scholar
  166. 166.
    Cristiano P. Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm 1984; 18: 314–316.PubMedGoogle Scholar
  167. 167.
    Hooper CA, Haney BB, Stone HH. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole [letter]. Lancet 1980; 1: 39, 40.Google Scholar
  168. 168.
    Pakter RL, Russell TR, Mielke CH, et al. Coagulopathy associated with the use of moxalactam. JAMA 1982; 248: 1100.PubMedGoogle Scholar
  169. 169.
    Marier RL, Faro S, Sanders CV, et al. Moxalactam in the therapy of serious infections. Antimicrob Agents Chemother 1982; 21: 650–654.PubMedGoogle Scholar
  170. 170.
    Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cefalosporins. Thrombosis and Haemost 1984; 51: 358–361.Google Scholar
  171. 171.
    Frick P, Riedler G, Brogli H. Dose response and minimal daily requirement for vitamin K in man. Applied Physiol. 1967; 23: 387–389.Google Scholar
  172. 172.
    Lipsky J. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic associated hypothrombinemia. Lancet 1983; 2: 192, 193.Google Scholar
  173. 173.
    Lipsky J, Lewis J, Novick W. Production of hypoprothrombinemia by moxalactam and 1-methyl-5-thiotetrazole in rats. Antimicrob Agents Chemother 1984; 25: 380, 381.Google Scholar
  174. 174.
    Angaran DM, Dias VC, Arom KV, et al. The influence of prophylactic antibiotics on the warfarin anticoagulation response in the postoperative prosthetic cardiac valve patient. Cefamandole versus vancomycin. Ann Surg 1984; 199: 107–111.PubMedGoogle Scholar
  175. 175.
    Angaran DM, Virgil MS, Dias VC. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Ann Surg 1987; 206: 155–161.PubMedGoogle Scholar
  176. 176.
    Verhagen CA, Mattie H, Van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol 1994; 37: 193–197.PubMedGoogle Scholar
  177. 177.
    Luthy R, Blaser J, Bonetti A, et al. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 1981; 20: 567–575.PubMedGoogle Scholar
  178. 178.
    LeBel M, Paone RP, Lewis GP. Effect of probenecid on the pharmacokinetics of ceftizoxime. J Antimicrob Chemother 1983; 12: 147–155.PubMedGoogle Scholar
  179. 179.
    Reeves DS, Bullock DW, Bywater MJ, et al. The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers. Br J Clin Pharm 1981; 11: 353–359.Google Scholar
  180. 180.
    Marino EL, Dominquez-Gil A. The pharmacokinetics of cefadroxil associated with probenecid. Int J Clin Pharmacol Ther Toxicol 1981; 19: 506–508.PubMedGoogle Scholar
  181. 181.
    Stoeckel K. Pharmacokinetics of Rocephin®, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 1981; 27: 42–46.PubMedGoogle Scholar
  182. 182.
    Kaplan KS, Reisberg BE, Weinstein L. Cephaloridine: antimicrobial activity and pharmacologic behavior. Am J Med Sci 1967; 253: 667–674.PubMedGoogle Scholar
  183. 183.
    Duncan WC. Treatment of gonorrhoea with cefazolin plus probenecid. J Infect Dis 1974; 130: 398–401.PubMedGoogle Scholar
  184. 184.
    Mischler TW, Sugerman AA, Willard SA, Barmick L, Neiss ES. Influence of probenecid and food on the bioavailability of cephradine in normal male subjects. J Clin Pharmacol 1974; 14: 604–611.PubMedGoogle Scholar
  185. Tuano SB, Brodie JL. Kirby WM. Cephaloridine versus cephalothin: relation of the kidney to blood level differences after parenteral administration. Antimicrob Agents Chemother 1966;6:101–106.Google Scholar
  186. 186.
    Griffith RS, Black HR, Brier GL, et al. Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob Agents Chemother 1977; 11: 809–812.PubMedGoogle Scholar
  187. 187.
    Bint AJ, Reeves DS, Holt HA. Effect of probenecid on serum cefoxitin concentrations. J Antimicrob Chemother 1977; 3: 627, 628.Google Scholar
  188. 188.
    Taylor WA, Holloway WJ. Cephalexin in the treatment of gonorrhoea. Int J Clin Pharmacol 1972; 6: 7–9.PubMedGoogle Scholar
  189. 189.
    Ko H, Cathcart KS, Griffith DL, et al. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother 1989; 33: 356–361.PubMedGoogle Scholar
  190. 190.
    Vlasses PH, Holbrook AM, Schrogie J, et al. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother 1980; 17: 847–855.PubMedGoogle Scholar
  191. 191.
    Stoeckel K, Trueb V, Dubach UC, et al. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol 1988; 34: 151–156.PubMedGoogle Scholar
  192. 192.
    O’Callaghan CH, Acred P, Harper PB, et al. GR 20263, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob Agents Chemother 1980; 17: 876–883.PubMedGoogle Scholar
  193. 193.
    DeSante KA, Israel KS, Brier GL, et al. Effect of probenecid on the pharmacokinetics of moxalactam. Antimicrob Agents Chemother 1982; 21: 58–61.PubMedGoogle Scholar
  194. 194.
    Patel IH, Soni PP, Carbone JJ, et al. Lack of probenecid effect on nonrenal excretion of ceftriaxone in anephric patients. J Clin Pharmacol 1990; 30: 449–453.PubMedGoogle Scholar
  195. 195.
    Kercsmar CM, Stern RC, Reed MD, et al. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother 1983; 12: 289–295.PubMedGoogle Scholar
  196. 196.
    Jovanovich JF, Saravolatz LD, Burch K, et al. Failure of probenecid to alter the pharmacokinetics of ceforanide. Antimicrob Agents Chemother 1981; 20: 530–532.PubMedGoogle Scholar
  197. 197.
    Pfeifer HJ, Greenblatt DJ, Friedman P. Effects of three antibiotics on theophylline kinetics. Clin Pharmacol Ther 1979; 26: 36–40.PubMedGoogle Scholar
  198. 198.
    Bachmann K, Schwartz J, Forney RB, et al. Impact of cefaclor on the pharmacokinetics of theophylline. Ther Drug Monitor 1986; 8: 151–154.Google Scholar
  199. 199.
    Jonkman JH, Van der Boon WJ, Schoenmaker R, et al. Clinical pharmacokinetics of theophylline during co-treatment with cefaclor. Int J Clin Pharmacol Ther Toxicol 1986; 24: 88–92.PubMedGoogle Scholar
  200. 200.
    Hammond D, Abate MA. Theophylline toxicity, acute illness, and cefaclor. Drug Intell Clin Pharm 1989; 23: 339, 340.Google Scholar
  201. 201.
    Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989: 24: 311–320.PubMedGoogle Scholar
  202. 202.
    Drusano GL, Stadiford HC. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med 1985: 78: 47–53.PubMedGoogle Scholar
  203. 203.
    Bösmuller C, Steurer W, Königsrainer A, et al. Increased risk of central nervous system toxicity in patients treated with cyclosporin and imipenem/cilastatin. Nephron 1991; 58: 362–364.PubMedGoogle Scholar
  204. 204.
    Zazgornik J, Schein W, Heimberger K, et al. Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporin therapy in a kidney transplant recipient-synergism of side effects or drug interaction. Clin Nephrol 1986; 26: 265, 266.Google Scholar
  205. 205.
    Mraz W, Sido B, Knedel M, et al. Concomitant immunosuppressive and antibiotic therapy-reduction of cyclosporin A blood levels due to treatment with imipenem/ cilastatin. Transplant Proc 1992; 24: 1704–1708.PubMedGoogle Scholar
  206. 206.
    Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J 1991; 84: 465–468.PubMedGoogle Scholar
  207. 207.
    PrimaxinTM packet insert. Merck & Co, 1998.Google Scholar
  208. 208.
    De Turck BJ, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin [letter]. J Antimicrob Chemother 1998; 42: 563–564.PubMedGoogle Scholar
  209. 209.
    Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 1997; 39: 295, 296.Google Scholar
  210. 210.
    AzactamTM packet insert. Bristol-Myers Squibb Company, 1999.Google Scholar
  211. 211.
    Swabb EA, Sugarman AA, Frantz M, et al. Renal handling of the monobactam aztreonam in healthy subjects. Clin Pharmacol Ther 1983; 33: 609–613.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Melinda M. Neuhauser
  • Larry H. Danziger

There are no affiliations available

Personalised recommendations